📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. (2023)

First Author: Szubert AJ

Attributed to: saRNA SARS-CoV-2 vaccine funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2022.101823

PubMed Identifier: 36684396

Publication URI: http://europepmc.org/abstract/MED/36684396

Type: Journal Article/Review

Volume: 56

Parent Publication: EClinicalMedicine

ISSN: 2589-5370